Oral transmucosal fentanyl citrate for the treatment of breakthrough pain in cancer patients: An overview of its pharmacological and clinical characteristics
| Autor: | Kyriaki Mystakidou, Emmanuela Katsouda, Efi Parpa, Marinos L. Tsiatas, Lambros Vlahos |
|---|---|
| Rok vydání: | 2005 |
| Předmět: |
Time Factors
Breakthrough Pain Administration Oral Pain law.invention 03 medical and health sciences 0302 clinical medicine Pharmacokinetics 030502 gerontology law Neoplasms Humans Medicine Pharmacology (medical) Pain Measurement Clinical Trials as Topic Clinical pharmacology Dose-Response Relationship Drug business.industry Palliative Care Mouth Mucosa Cancer General Medicine medicine.disease FentaNYL Citrate Pain Intractable Review article Analgesics Opioid Fentanyl Treatment Outcome Anesthesiology and Pain Medicine Opioid 030220 oncology & carcinogenesis Pharmacodynamics Anesthesia 0305 other medical science business medicine.drug |
| Zdroj: | Journal of Opioid Management. 1:36-40 |
| ISSN: | 1551-7489 |
| DOI: | 10.5055/jom.2005.0010 |
| Popis: | Breakthrough pain is a transitory flare of pain occurring in most cancer patients against a background of otherwise controlled persistent pain. Treatment of breakthrough pain is a challenging phenomenon. Oral transmucosal fentanyl citrate (Actiq ® , Cephalon, Inc., West Chester, PA), a new opioid formulation with a unique delivery system, reflects the characteristics of breakthrough pain (rapid onset of action and short duration), making it an effective treatment for cancer patients who already receive opioids and experience flares of pain. This review article aims to present the role of oral transmucosal fentanyl citrate in the management of breakthrough pain in cancer patients. In particular, it is going to discuss the synthesis, clinical pharmacology, pharmacokinetic and pharmacodynamic properties, toxicity, and clinical efficacy of this novel agent. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|